The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.
 
Els Van Nieuwenhuysen
Consulting or Advisory Role - AstraZeneca (Inst); Oncoinvent; Regeneron (Inst)
Research Funding - AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncoinvent (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Regeneron (Inst)
 
Sara Bouberhan
Consulting or Advisory Role - Immunogen
 
Konstantinos Papadimitriou
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Merck; Novartis; Roche
 
Rebecca Christian Arend
Employment - Signatera (I)
Consulting or Advisory Role - Caris Life Sciences; GlaxoSmithKline; KIYATEC; Leap Therapeutics; Merck; Seagan; Sutro Biopharma; VBL Therapeutics
Research Funding - Champions Oncology; Exelixis; GlaxoSmithKline; Immunogen; Merck
Travel, Accommodations, Expenses - Caris Life Sciences; GlaxoSmithKline; VBL Therapeutics
 
Jung-Yun Lee
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); ImmunoGen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
Roisin Eilish O'Cearbhaill
Honoraria - Aptitude Health; Curio Science; GlaxoSmithKline; GOG Foundation; MJH/PER
Consulting or Advisory Role - 2seventy bio; Carina Biotech; GlaxoSmithKline; GOG Foundation; Immunogen; Loxo/Lilly; Miltenyi Biotec; R-Pharm; Seagan
Research Funding - Acrivon Therapeutics (Inst); alkermes (Inst); ArsenalBio (Inst); AstraZeneca/Merck (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Context Therapeutics (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Ludwig Institute for Cancer Research (Inst); Lyell Immunopharma (Inst); Merck/Genentech (Inst); Regeneron (Inst); Sellas Life Sciences (Inst); Syndax (Inst); TapImmune Inc. (Inst); TCR2 Therapeutics (Inst)
Travel, Accommodations, Expenses - Gathering Around Cancer; Society of Gynecologic Oncology
Other Relationship - JAMA Oncology
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; AstraZeneca; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Umoja Biopharma; Verastem
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; Eisai; GlaxoSmithKline; Immunomedics; LEK; MSD Oncology; Myriad Genetics; Novartis; Roche/Genentech; Seagen; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); NOVARTIS (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech; SEAGEN
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Alkermes; Amgen; AstraZeneca; Clovis Oncology; Genmab; Hedera Dx; Immunogen; Kartos Therapeutics; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK; Tubulis GmbH
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
 
Judith Michels
Consulting or Advisory Role - Brenus Pharma; GlaxoSmithKline; Regeneron Pharmaceuticals, Inc.;
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Merck
 
Linda R. Mileshkin
Research Funding - BeiGene (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - Roche
 
Yeh Chen Lee
Speakers' Bureau - AstraZeneca
Research Funding - BeiGene (Inst)
 
Rowan Miller
Consulting or Advisory Role - AZD; Clovis Oncology; Ellipses Pharma; GlaxoSmithKline; Merck KGaA; Roche
Speakers' Bureau - AZD; Clovis Oncology; GlaxoSmithKline; Roche
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Suk-Young Yoo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Mary Jane Peterman
Employment - Regeneron
Stock and Other Ownership Interests - Merck; Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Tamara Schmidt
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
David Knorr
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Thomas S. Uldrick
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Elizabeth Miller
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron